Early Multimodal Therapy and Mechanical Ventilation

Launched by FUNDACIÓN SANTA FE DE BOGOTA · Nov 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of early multimodal therapy on patients in the Intensive Care Unit (ICU) who need mechanical ventilation, which is a machine that helps them breathe. The goal is to see if starting this therapy early can reduce the amount of time patients spend on the ventilator. The trial will take place at Fundación Santa Fe de Bogotá and is currently not recruiting participants yet, but it aims to help critically ill patients who are in need of intensive care.

To be eligible for this study, patients must be adults in the ICU who require mechanical ventilation through a breathing tube for more than 72 hours and are expected to need it for at least another day. They should also have a Barthel Index score of 70 or higher, which measures their ability to perform daily activities. However, there are specific criteria that would exclude patients from participating, such as those with certain medical conditions or those who have had specific surgeries. If eligible, participants can expect to receive specialized care and monitoring to evaluate how this early treatment approach may help improve their recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The inclusion criteria are as follows:
• • Patients hospitalized in the adult intensive care unit of the Fundación Santa Fe de Bogotá.
• • Requirement of invasive mechanical ventilation through an endotracheal tube for a period exceeding 72 hours with an expected continuation of at least 24 hours.
• • Barthel Index equal to or greater than 70
• Exclusion Criteria:
• Exclusion criteria:
• • Patients requiring invasive mechanical ventilation through a tracheostomy tube or nasotracheal tube.
• • Patients who have undergone any type of head and neck surgery.
• • Cardiac arrest.
• • Airway burn.
• • Burns with an extent greater than 50% of the body surface area.
• • Patients with chronic obstructive pulmonary disease.
• • Patients referred from another institution.
• • Demyelinating or neuromuscular junction diseases.
• • Patients requiring neuromuscular blockade.
• • Patients with a life expectancy of less than 180 days.
• • Patients deemed by medical criteria not to benefit from multimodal treatment.
• • Patients not entering the ICU for the first time.
• • Patients participating in other clinical rehabilitation trials